CNS PHARMACEUTICALS, INC. (CNSP): Price and Financial Metrics


CNS PHARMACEUTICALS, INC. (CNSP): $1.00

0.01 (+0.63%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CNSP Stock Price Chart Interactive Chart >

Price chart for CNSP

CNSP Price/Volume Stats

Current price $1.00 52-week high $13.43
Prev. close $0.99 52-week low $0.95
Day low $0.95 Volume 74,100
Day high $1.06 Avg. volume 45,792
50-day MA $1.73 Dividend yield N/A
200-day MA $4.82 Market Cap 13.29M

CNS PHARMACEUTICALS, INC. (CNSP) Company Bio


CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. Its product pipeline includes berubicin, and CNS-12. The company was founded by Waldemar Priebe in July 2017 and is headquartered in Houston, TX.


CNSP Latest News Stream


Event/Time News Detail
Loading, please wait...

CNSP Latest Social Stream


Loading social stream, please wait...

View Full CNSP Social Stream

Latest CNSP News From Around the Web

Below are the latest news stories about CNS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CNSP as an investment opportunity.

CNS Pharmaceuticals to Present at the Virtual Investor GBM Spotlight Event

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that it will present at the Virtual Investor GBM Spotlight Event on Tuesday, April 4, 2023 at 3:00 PM ET.

Yahoo | March 29, 2023

CNS Pharmaceuticals Announces it Has No Exposure to Silicon Valley Bank Issues

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that it is aware that the Federal Deposit Insurance Corp. has taken control of Silicon Valley Bank ("SVB") due to liquidity concerns. The Company does not hold any deposits or investments at SVB.

Yahoo | March 13, 2023

CNS Pharmaceuticals Continues Momentum in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM with First Patient Enrolled in Switzerland

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that the first patient in Switzerland has been enrolled in the Company's ongoing potentially pivotal global trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.

Yahoo | March 9, 2023

CNS Pharmaceuticals Announces First Patient Enrolled in Spain in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that the first patient in Spain has been enrolled in the Company's ongoing potentially pivotal global trial evaluating Berubicin for the treatment of recurrent glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.

Yahoo | February 7, 2023

CNS Pharmaceuticals Announces Investigator-Initiated Phase 1b/2 Trial to be Conducted at the Pomeranian Medical University in Poland

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced an investigator-initiated Phase 1b/2 trial evaluating the Company's novel anthracycline, Berubicin, which will be conducted at the Pomeranian Medical University (PUM) in Szczecin, Poland.

Yahoo | January 12, 2023

Read More 'CNSP' Stories Here

CNSP Price Returns

1-mo -45.95%
3-mo -58.33%
6-mo -81.38%
1-year -90.28%
3-year -98.41%
5-year N/A
YTD -58.33%
2022 -88.61%
2021 -60.54%
2020 -54.94%
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7368 seconds.